Sign In
Buy NNVC
$1.31
-0.0100 (-0.758%)
At Close: Jun 23, 2026
NanoViricides' NV-387 could provide a crucial missing weapon in the fight against US measles outbreak
07:11am, Tuesday, 04'th Mar 2025
NanoViricides (NYSE-A:NNVC) believes its broad-spectrum antiviral NV-387 could provide a crucial weapon piece in the fight against the ongoing measles outbreak in the US. The company responded to a re
SHELTON, CT / ACCESS Newswire / March 4, 2025 / The HHS Department Secretary Robert F. Kennedy Jr. wrote an Opinion piece in the FoxNews entitled "Measles outbreak is call to action for all of us".
NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials
09:40am, Wednesday, 19'th Feb 2025
NanoViricides (NYSE-A:NNVC) is positioning itself for a pivotal year in 2025, with plans to advance its lead antiviral candidate, NV-387, into multiple Phase II clinical trials. The company is plannin
NanoViricides, Inc. Has Filed its Quarterly Report
06:30am, Wednesday, 19'th Feb 2025
Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu SHELTON, CT / ACCESS Newswire / February 19, 2025 / NanoViricides, Inc. (NYSE
NanoViricides announces readiness to combat bird flu with antiviral drug NV-387
08:41am, Tuesday, 11'th Feb 2025
NanoViricides (NYSE-A:NNVC) stated today that it is prepared to address the escalating threat of bird flu with its broad-spectrum antiviral drug, NV-387. The company asserts that NV-387 is designed to
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
06:30am, Tuesday, 11'th Feb 2025
SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum
NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387
03:33pm, Tuesday, 04'th Feb 2025
With its broad-spectrum antiviral drug NV-387, NanoViricides (NYSE-A:NNVC) sees a future where patients with a range of viral diseases can access treatment as quickly as they can secure antibiotics f
NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts
08:31am, Friday, 31'st Jan 2025
Bird flu is likely widespread among birds in Massachusetts, State health and environmental officials said this week on Wednesday, as new cases are reported in both wild and domestic birds across multi
NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
06:30am, Wednesday, 29'th Jan 2025
SHELTON, CT / ACCESS Newswire / January 29, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the vi
NanoViricides taps clinical research organization for Phase II trial of NV-387
09:20am, Monday, 27'th Jan 2025
NanoViricides (NYSE-A:NNVC) said on Monday it had engaged a clinical research organization to conduct a Phase II trial for its broad-spectrum antiviral drug NV-387. The Connecticut-based company is ta
NanoViricides Engages CRO for Phase II Clinical Trial
06:30am, Monday, 27'th Jan 2025
SHELTON, CT / ACCESS Newswire / January 27, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phas
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
06:30am, Monday, 13'th Jan 2025
SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus c
NanoViricides CEO discusses NV-387's broad spectrum promise - ICYMI
08:01am, Saturday, 11'th Jan 2025
NanoViricides (NYSE-A:NNVC) CEO Dr Anil Diwan joined Proactive to highlight the company's lead drug candidate NV-387, which is targeting multiple viral families by mimicking receptors essential for vi
NanoViricides highlights urgent need for broad-spectrum antiviral solutions amid viral threats
09:03am, Wednesday, 08'th Jan 2025
NanoViricides (NYSE-A:NNVC) has highlighted the growing need for innovative antiviral solutions amid rising concerns over multiple viral threats, including H5N1 bird flu, COVID-19, RSV, and human meta
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
06:30am, Wednesday, 08'th Jan 2025
SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), comments on the many viruses that could cause pandemics that are go
